# Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

> **NCT04518228** · — · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 205 (actual)

## Conditions studied

- HIV Infections
- Tuberculosis

## Interventions

- **DRUG:** Bictegravir (BIC)
- **DRUG:** Tenofovir alafenamide (TAF)
- **DRUG:** Cabotegravir (CAB)
- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Atazanavir/ritonavir (ATV/r)
- **DRUG:** Darunavir/ritonavir (DRV/r)
- **DRUG:** Lopinavir/ritonavir (LPV/r)
- **DRUG:** Cobicistat
- **DRUG:** Ritonavir
- **DRUG:** First-Line TB Treatment
- **DRUG:** Second-Line TB Treatment
- **DRUG:** Doravirine (DOR)

## Key facts

- **NCT ID:** NCT04518228
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-07-10
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518228, "Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04518228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*